Basic Information
IDELVION POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 500IU/VIAL
INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION
Regulatory Information
SIN15812P
September 19, 2019
Prescription Only
Therapeutic
INTRAVENOUS
August 10, 2023
June 4, 2025
XB02BD04
Company Information
Active Ingredients
albutrepenonacog alfa
Strength: 500IU/vial
Detailed Information
Contraindications
**4.3 Contraindications** IDELVION is contraindicated in patients who have a known hypersensitivity to IDELVION, any of its components, excipients or hamster protein (see section 6.1 – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_).
Indication Information
**4.1 Therapeutic indications** Prophylaxis and treatment of bleeding in patients with haemophilia B (congenital factor IX deficiency) including control and prevention of bleeding in surgical settings.